Comparative Pharmacology
Head-to-head clinical analysis: GATIFLOXACIN versus MOXAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GATIFLOXACIN versus MOXAM.
GATIFLOXACIN vs MOXAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gatifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
400 mg orally or intravenously once daily
400 mg orally every 24 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life 7-14 hours (mean ~10 hours in healthy adults); prolonged in renal impairment (up to 40 hours with CrCl <30 mL/min)
Clinical Note
moderateGatifloxacin + Digoxin
"Gatifloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateGatifloxacin + Digitoxin
"Gatifloxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateGatifloxacin + Deslanoside
"Gatifloxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateGatifloxacin + Acetyldigitoxin
"Gatifloxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 6-8 hours; prolonged in renal impairment (up to 20 hours with CrCl <30 mL/min).
Primarily renal excretion (70-87% unchanged in urine) via glomerular filtration and tubular secretion; ~10% biliary/fecal
Renal: ~70% unchanged; biliary/fecal: ~20% as unchanged drug and metabolites; minor metabolism via glucuronidation.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic